- Home
- ABBV vs JNJ Comparison
ABBV vs JNJ Comparison
Compare ABBV & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABBV
- JNJ
- Stock Information
- Founded
- ABBV 2012
- JNJ 1886
- Country
- ABBV United States
- JNJ United States
- Employees
- ABBV N/A
- JNJ N/A
- Industry
- ABBV Biotechnology: Pharmaceutical Preparations
- JNJ Biotechnology: Pharmaceutical Preparations
- Sector
- ABBV Health Care
- JNJ Health Care
- Exchange
- ABBV Nasdaq
- JNJ Nasdaq
- Market Cap
- ABBV 338.3B
- JNJ 373.9B
- IPO Year
- ABBV N/A
- JNJ 1944
- Fundamental
- Price
- ABBV $185.08
- JNJ $152.02
- Analyst Decision
- ABBV Buy
- JNJ Buy
- Analyst Count
- ABBV 22
- JNJ 16
- Target Price
- ABBV $213.14
- JNJ $169.33
- AVG Volume (30 Days)
- ABBV 6.3M
- JNJ 8.3M
- Earning Date
- ABBV 07-24-2025
- JNJ 07-16-2025
- Dividend Yield
- ABBV 3.51%
- JNJ 3.42%
- EPS Growth
- ABBV N/A
- JNJ N/A
- EPS
- ABBV 2.34
- JNJ 8.98
- Revenue
- ABBV $57,367,000,000.00
- JNJ $89,331,000,000.00
- Revenue This Year
- ABBV $8.48
- JNJ $3.87
- Revenue Next Year
- ABBV $8.19
- JNJ $4.14
- P/E Ratio
- ABBV $77.91
- JNJ $16.96
- Revenue Growth
- ABBV 5.45
- JNJ 4.30
- 52 Week Low
- ABBV $163.52
- JNJ $140.68
- 52 Week High
- ABBV $218.66
- JNJ $169.99
- Technical
- Relative Strength Index (RSI)
- ABBV 43.37
- JNJ 46.60
- Support Level
- ABBV $181.73
- JNJ $150.73
- Resistance Level
- ABBV $188.99
- JNJ $157.67
- Average True Range (ATR)
- ABBV 3.63
- JNJ 2.03
- MACD
- ABBV -0.57
- JNJ -0.22
- Stochastic Oscillator
- ABBV 14.33
- JNJ 38.82
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.